Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | July 15, 2026

Jul 15, 2026

•

3 min read

Biotech & Pharma Updates | July 15, 2026

🧬 FDA approves Celcuity's Revtorpyk (gedatolisib) for PI3K pathway hormone receptor-positive, HER2-negative metastatic breast cancer after Ph3 success, Insilico Medicine, Bora Pharmaceuticals partner on AI drug discovery and commercialization, deal worth $2.5B, Kelun-Biotech's (sacituzumab tirumotecan) plus Merck & Co.'s Keytruda meets primary endpoint in Ph3 for PD-L1-negative non-squamous non-small cell lung cancer

Christian Cuchapin, +1

Biotech & Pharma Updates | July 14, 2026

Jul 14, 2026

•

3 min read

Biotech & Pharma Updates | July 14, 2026

🧬 Biogen's (diranersen) Ph2 results show tau-targeting antisense oligonucleotide slows decline in Alzheimer's disease, AstraZeneca, Dizal Pharmaceutical strike exclusive global lung cancer license deal, $600M upfront, up to $1.5B total, Biogen, Eisai win FDA approval for subcutaneous Leqembi (lecanemab) initiation therapy in Alzheimer's disease

Christian Cuchapin, +1

Biotech & Pharma Updates | July 13, 2026

Jul 13, 2026

•

3 min read

Biotech & Pharma Updates | July 13, 2026

🧬 FDA expands Pfizer and Astellas' Padcev (enfortumab vedotin-ejfv) plus Merck & Co.'s Keytruda (pembrolizumab) label to all muscle-invasive bladder cancer patients regardless of cisplatin eligibility, Bayer, Apollo strike €3B ($3.43B) equity deal for minority stake in LARC contraceptives business, CMS, Insilico partner on AI-driven CNS drug discovery, $177M milestones

Christian Cuchapin, +1

Biotech & Pharma Updates | July 10, 2026

Jul 10, 2026

•

3 min read

Biotech & Pharma Updates | July 10, 2026

🧬 Sanofi's Sarclisa Escena (isatuximab) wins FDA approval as first on-body injector anticancer drug for multiple myeloma, GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) Ph3 trial meets overall survival endpoint in small cell lung cancer, ARPA-H awards up to $160M to teams developing personalized genetic medicines for rare diseases

Christian Cuchapin, +1

Jul 9, 2026

•

3 min read

Biotech & Pharma Updates | July 9, 2026

🧬 Ipsen's Dysport (abobotulinumtoxinA) meets Ph3 goals in both episodic and chronic migraine trials, Sanofi offers EU concessions to halt probe over misleading flu vaccine campaign against CSL Seqirus, MindRank raises $52M Series B, advancing AI-discovered oral GLP-1 obesity pill to Phase III

Christian Cuchapin, +1

Jul 8, 2026

•

3 min read

Biotech & Pharma Updates | July 8, 2026

🧬 Vera Therapeutics' Trutakna (atacicept) receives FDA accelerated approval for IgA nephropathy targeting APRIL and BAFF, AstraZeneca, Sino Biopharmaceutical strike ex-China licensing deal for COPD candidate TQC3721, $200M upfront, up to $1.9B total, Evonik invests $100M in Indiana API plant to meet surging U.S. CDMO demand

Christian Cuchapin, +1

Jul 7, 2026

•

3 min read

Biotech & Pharma Updates | July 7, 2026

🧬 Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B in largest-ever deal, expanding into endocrine diseases, Kalohexis files confidential IPO, developing melanocortin-based obesity and cancer cachexia treatments, Compass Pathways' COMP360 (psilocybin) demonstrates durable Ph3 response in treatment-resistant depression

Christian Cuchapin, +1

Jul 6, 2026

•

3 min read

Biotech & Pharma Updates | July 6, 2026

🧬 Novartis to acquire Myricx Bio for up to $1.5B, expanding ADC cancer pipeline with novel NMT inhibitor payloads, Scribe Therapeutics files for IPO, advancing lipid-lowering genetic medicines through clinical trials, Celea Therapeutics raises $180M venture round to advance IPF drug deupirfenidone into late-stage trials

Christian Cuchapin, +1

Jul 2, 2026

•

3 min read

Biotech & Pharma Updates | July 2, 2026

🧬 Roche's (divarasib) beats Amgen's Lumakras and BMS's Krazati in Ph3 KRAS G12C-mutated non-small cell lung cancer trial, BridgeBio attracts $1B in convertible preferred equity from Sixth Street, HealthCare Royalty for drug launches, AstraZeneca, CSPC Pharmaceutical Group partner on siRNA kidney disease therapies, $30M upfront, $1.77B total

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | July 15, 2026

Biotech & Pharma Updates | July 14, 2026

Biotech & Pharma Updates | July 13, 2026

Biotech & Pharma Updates | July 10, 2026

Biotech & Pharma Updates | July 9, 2026

Biotech & Pharma Updates | July 8, 2026

Biotech & Pharma Updates | July 7, 2026

Biotech & Pharma Updates | July 6, 2026

Biotech & Pharma Updates | July 2, 2026

TLDR Biotech

FAQ

Media Partners